Patent assignee · US · COMPANY

Atea Pharmaceuticals, Inc.

🏢 View company profile →
23Patents
23Active
23Granted
49Portfolio score

Filing activity: Mar 7, 2016 → Jul 24, 2023

Most-cited patents

PatentTitleAreaCited byStatus
US9828410B2 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 18 Active
US10519186B2 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Chemistry; Metallurgy 14 Active
US10005811B2 β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 13 Active
US10000523B2 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 13 Active
US10874687B1 Highly active compounds against COVID-19 Chemistry; Metallurgy 13 Active
US10239911B2 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 12 Active
US10815266B2 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 4 Active
US10870672B2 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 3 Active
US10875885B2 β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 3 Active
US10870673B2 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 3 Active
US10946033B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Emerging Cross-Sectional Technologies 3 Active
US10906928B2 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Chemistry; Metallurgy 2 Active
US10202412B2 β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections Chemistry; Metallurgy 2 Active
US10894804B2 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Chemistry; Metallurgy 2 Active
US11813278B2 Highly active compounds against COVID-19 Chemistry; Metallurgy 1 Active
US11738038B2 Highly active compounds against COVID-19 Chemistry; Metallurgy 1 Active
US11690860B2 Treatment of HCV infected patients with cirrhosis Human Necessities 1 Active
US11707480B2 Highly active compounds against COVID-19 Chemistry; Metallurgy 1 Active
US12084473B2 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Chemistry; Metallurgy 0 Active
US12226429B2 Highly active compounds against COVID-19 Chemistry; Metallurgy 0 Active
US11975016B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Emerging Cross-Sectional Technologies 0 Active
US10711029B2 Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection Human Necessities 0 Active
US12006340B2 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.